Last week, shares of Cologuard dropped following a U.S. Preventative Services Task Force rating announcement. But, a new study of patient preferences could affect the USPSTF's final recommendations, according to a Milwaukee Business Journal report.
The study, conducted by Case Western Reserve University School of Medicine in Cleveland, examined patient preferences for colorectal cancer screening modalities. Three-quarters of patients prefer stool DNA testing over colonoscopy, according to the study published in the journal Family Medicine and Community Health. Additionally, 84 percent of patients polled would repeat stool DNA testing if a provider recommended it.
Analysts Jeffrey Elliot and Catherine Ramsay of Robert W. Baird & Co. indicate the study's results could have a positive impact Cologuard's position with the USPSTF, according to the Milwaukee Business Journal.